Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 10/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15110502 | 0.71 | SLC9A1 (0.51) | — | |
| SCHEMBL28676104 | 0.70 | P2RX4 (0.50) | KMT2AP2RX4MEN1L3MBTL1 | |
| SCHEMBL4171496 | 0.70 | P2RX4 (0.50) | KMT2AP2RX4MEN1L3MBTL1 | |
| SCHEMBL17241980 | 0.69 | MAPT (0.52) | KMT2AMEN1 | |
| SCHEMBL12990649 | 0.69 | CA12 (0.50) | KCNJ1KCNH2KMT2AMEN1 | |
| SCHEMBL6493969 | 0.68 | HRH3 (0.52) | KCNJ1KCNH2HRH3KMT2AMEN1 | |
| SCHEMBL6926451 | 0.68 | SLC9A1 (0.52) | L3MBTL1 | |
| SCHEMBL16581427 | 0.67 | ADORA2A (0.48) | L3MBTL1 | |
| SCHEMBL3292782 | 0.67 | TSHR (0.75) | KCNJ1KCNH2HRH3TSHR | |
| SCHEMBL4772758 | 0.67 | ADORA2B (0.50) | KMT2ATSHRMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212212-A1 | PROCESSES FOR PREPARING OLIGONUCLEOTIDES | SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212212-A1 | PROCESSES FOR PREPARING OLIGONUCLEOTIDES | XRN2, UPF1, NSUN2 | KCNJ1 3467/4885KCNH2 3744/4885HRH3 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.